Ep #6 | From Google to Drug Discovery with AI: Why "Science Advances One Funeral at a Time" | Javier Tordable

Early-stage drug discovery can take years and requires deep expertise in computational chemistry that most biologists don't have. This creates a massive bottleneck in getting new therapies from concept to testing.

In this episode, Ayush Mishra sits down with Javier Tordable, Founder & CEO of Pauling.AI, to explore how AI is automating the most time-intensive parts of drug discovery and why adoption remains the industry's biggest challenge.

You will hear insights on:

• Why he left 16 years at Google to focus entirely on pharmaceutical AI
• How rational drug design works and where the traditional process breaks down
• What Pauling.AI does differently, an AI agent that handles target identification, molecular design, and binding predictions like ChatGPT handles text
• The real resistance AI faces from veteran scientists and the uncomfortable truth about generational change in pharma
• When we can expect to see the first fully AI-designed drugs receive FDA approval
• Where emerging market founders can find datasets when premium pharmaceutical data is locked behind paywalls
• What human scientists will always do better than AI, and why that matters
• His brutally honest take on the "science advances one funeral at a time" phenomenon
• Practical advice for biotech entrepreneurs building AI healthcare companies in Asia and Africa

If you work in pharma R&D, drug discovery, biotech innovation, computational chemistry, or clinical development strategy, this conversation offers an unfiltered view of where AI is actually taking pharmaceutical research.

Javier Tordable's LinkedIn: https://www.linkedin.com/in/jtordable/ 

Ayush Mishra's LinkedIn: https://www.linkedin.com/in/ayushmishra/ 

Watch Now on YouTube